- Sep 30 Fri 2011 05:02
- Sep 29 Thu 2011 05:00
- Sep 27 Tue 2011 05:59
The European Medicines Agency (EMA) recommends restricting the use of the antiarrhythmic medication dronedarone (Multaq, Sanofi-Aventis) . The committee states that because of the increased risk of liver, lung, and cardiovascular adverse events, dronedarone "should only be prescribed after alternative treatment options have been considered." Patients currently taking dronedarone should have their treatment reassessed by their physician at their next scheduled visit, the EMA reports.
- Sep 26 Mon 2011 05:56
The US Food and Drug Administration (FDA) today approved eculizumab (Soliris, Alexion Pharmaceuticals) as the first drug to treat atypical hemolytic uremic syndrome (aHUS), a rare and chronic blood disease that disproportionately affects children.
- Sep 25 Sun 2011 05:53
The European Medicines Agency has changed its recommendations for suppositories that contain terpenic derivatives. It now says that they should not be used in children younger than 30 months or in children who have experienced febrile convulsion, epilepsy, or recent anorectal lesions.
- Sep 23 Fri 2011 05:20
Arch Dermatol. 2011; 147(8):917-21 (ISSN: 1538-3652)
Fanelli M; Kupperman E; Lautenbach E; Edelstein PH; Margolis DJ
Department of Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, 815 Blockley Hall, 423 Guardian Dr, Philadelphia, PA 19104. firstname.lastname@example.org.
- Sep 22 Thu 2011 05:58
On August 10, the US Food and Drug Administration (FDA) approved Complera, a combination of the nonnucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine and the nucleoside reverse transcriptase inhibitors (NRTIs) tenofovir and emtricitabine, for treatment of HIV infection. This combination drug results in the same blood levels as each of the 3 drugs individually, according to the findings of a bioequivalence study. Approval of Complera was based on the ECHO and THRIVE phase 3 randomized trials of rilpivirine, without performance of any new trials.
- Sep 19 Mon 2011 05:16
- Sep 18 Sun 2011 06:03
- Sep 17 Sat 2011 06:45
- Sep 16 Fri 2011 05:32
Clinicians should avoid using the antinausea drug ondansetron (Zofran, GlaxoSmithKline) in patients with congenital long QT syndrome because they run a particular risk for an abnormal and potentially fatal heart rhythm called torsades de pointes, the US Food and Drug Administration (FDA) announced today.
- Sep 15 Thu 2011 05:36
- Sep 14 Wed 2011 04:32
- Sep 13 Tue 2011 06:42
Fifty million people in the world have epilepsy, and there are between 16 and 51 cases of new-onset epilepsy per 100,000 people every year.1 A community-based study in southern France estimated that up to 22.5% of patients with epilepsy have drug-resistant epilepsy.2 Patients with drug-resistant epilepsy have increased risks of premature death,3 injuries, psychosocial dysfunction, and a reduced quality of life.4,5 Here, we review recent progress in the understanding and management of drug-resistant epilepsy. Where appropriate, we have also graded the strength of evidence for specific treatments from class I (highest) to IV (lowest), according to guidelines from the American Academy of Neurology; the classification of evidence is described in Table 1 in the Supplementary Appendix (available with the full text of this article at NEJM.org).6
- Sep 11 Sun 2011 05:01
INTRODUCTION: HIV infection is a disease associated with chronic inflammation and immune activation. Antiretroviral therapy reduces inflammation, but not to levels in comparable HIV-negative individuals. The HMG-coenzyme A reductase inhibitors (statins) inhibit several pro-inflammatory processes and suppress immune activation, and are a logical therapy to assess for a possible salutary effect on HIV disease progression and outcomes.